Suvretta Capital Management LLC Makes New $1.12 Million Investment in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Suvretta Capital Management LLC bought a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 70,000 shares of the company's stock, valued at approximately $1,119,000. Suvretta Capital Management LLC owned about 0.06% of Centessa Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CNTA. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock worth $40,000 after acquiring an additional 826 shares during the period. GAMMA Investing LLC lifted its position in shares of Centessa Pharmaceuticals by 103.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company's stock worth $48,000 after purchasing an additional 1,509 shares during the period. Quarry LP boosted its stake in shares of Centessa Pharmaceuticals by 47.8% in the 2nd quarter. Quarry LP now owns 9,608 shares of the company's stock valued at $87,000 after purchasing an additional 3,108 shares during the last quarter. Sandia Investment Management LP acquired a new stake in shares of Centessa Pharmaceuticals during the second quarter worth $90,000. Finally, Fred Alger Management LLC bought a new position in Centessa Pharmaceuticals during the second quarter worth $99,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $17.66, for a total value of $176,600.00. Following the completion of the sale, the insider now owns 183,266 shares in the company, valued at $3,236,477.56. This represents a 5.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Saurabh Saha sold 1,671 shares of the business's stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $18.24, for a total transaction of $30,479.04. Following the transaction, the chief executive officer now owns 575,661 shares in the company, valued at approximately $10,500,056.64. This trade represents a 0.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 375,128 shares of company stock valued at $6,148,522. Corporate insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Stock Up 1.8 %

Shares of CNTA traded up $0.31 during trading hours on Friday, reaching $17.91. The stock had a trading volume of 526,808 shares, compared to its average volume of 417,585. The company has a market capitalization of $2.36 billion, a price-to-earnings ratio of -11.71 and a beta of 1.47. The firm has a 50-day simple moving average of $16.20 and a 200 day simple moving average of $12.60. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a 12 month low of $5.58 and a 12 month high of $18.74.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. Equities research analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CNTA has been the topic of a number of recent analyst reports. Morgan Stanley raised Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. Guggenheim boosted their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Friday, November 15th. Jefferies Financial Group raised their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, September 11th. B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a "buy" rating and a $33.00 target price on the stock. Finally, Oppenheimer restated an "outperform" rating and issued a $14.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.